Lonza, founded in 1897 and headquartered in Switzerland, is a leading global CDMO with a network of over 30 facilities and 17,500 employees across five continents. The company provides integrated development and manufacturing for small and large molecules, including mammalian and microbial biopharmaceuticals, cell and viral therapies, APIs, HPAPIs, and ADC payloads. Lonza’s services span process development, analytical method development, scale-up, GMP manufacturing, and specialized mRNA solutions with LNP formulation, supporting clients from discovery through commercial production.
